Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
10 mars 2022 07h05 HE
|
Aeterna Zentaris Inc
– Research agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis TORONTO, ONTARIO, March 10, 2022 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
26 janv. 2022 16h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
05 janv. 2022 08h36 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
23 déc. 2021 16h05 HE
|
Aeterna Zentaris Inc
– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) --...
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
04 nov. 2021 16h05 HE
|
Aeterna Zentaris Inc
– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
04 août 2021 16h05 HE
|
Aeterna Zentaris Inc
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong...
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
07 juin 2021 08h05 HE
|
Aeterna Zentaris Inc
– Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of...
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
03 juin 2021 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
17 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
05 mai 2021 16h35 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...